J Cancer 2017; 8(3):403-409. doi:10.7150/jca.17028 This issue Cite
Research Paper
1. Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China.
2. State Key Laboratory of Oncology in Southern China, Guangzhou, China.
3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
4. The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
5. The First Hospital of Foshan, Foshan, China.
*These authors contributed equally to this work.
Background: The purpose of this observational study was to evaluate the prognostic significance of the pre-treatment plasma fibrinogen level for survival outcomes in nasopharyngeal carcinoma (NPC).
Methods: A total of 998 patients with NPC treated at a single centre in China were retrospectively enrolled, of whom 182 (18.2%) developed distant metastasis during follow-up. Survival analyses were performed by the Kaplan-Meier method and Cox regression modelling to measure 3-year overall survival (OS) and distant metastasis-free survival (DMFS).
Results: Median OS for the entire cohort was 37.8 months. Using the cut-off value of 3.345 g/L identified in receiver operating curve analysis for fibrinogen, a high pre-treatment plasma fibrinogen level were associated with older age (P = 0.034), advanced TNM stage (P = 0.004) and development of distant metastasis (P < 0.001; Chi-square test). Multivariate Cox proportional hazard analysis demonstrated the pre-treatment plasma fibrinogen level was an independent significant prognostic factor for OS and DMFS in both the entire cohort and also among patients who developed distant metastasis during follow-up.
Conclusions: This study suggests the pre-treatment plasma fibrinogen level may serve as an independent prognostic marker to predict the survival outcomes of patients with NPC, including patients with metastatic disease.
Keywords: Nasopharyngeal carcinoma, metastasis, fibrinogen, prognosis.